Search
Ensitrelvir
go.drugbank.com/drugs/DB18834ApprovedInvestigationalEnsitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseInbakicept
go.drugbank.com/drugs/DB16479Investigational[L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin ( … [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without
Categories: Experimental Unapproved Treatments for COVID-19Poliovirus type 1 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10795ApprovedInvestigationalPoliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis
Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTIONPoliovirus type 3 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10797ApprovedInvestigationalPoliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis
Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTIONPralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalPralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.
Givosiran
go.drugbank.com/drugs/DB15066Approved[L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder … involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases.
Butabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawn[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety. … Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.
Amifostine
go.drugbank.com/drugs/DB01143ApprovedInvestigationalA phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Categories: Detoxifying Agents for Antineoplastic Treatment, Compounds used in a research, industrial, or household settingEtryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnIn the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesNevirapine
go.drugbank.com/drugs/DB00238ApprovedInvestigationalA potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use